Arcus Biosciences, Inc.
51
11
26
20
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
7.8%
4 terminated/withdrawn out of 51 trials
83.3%
-3.2% vs industry average
12%
6 trials in Phase 3/4
5%
1 of 20 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (51)
Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Role: lead
A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body
Role: lead
A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies
Role: lead
Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer
Role: collaborator
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
Role: lead
Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer
Role: lead
A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
Role: lead
Metabolism, Excretion, and Mass Balance Study of Quemliclustat in Healthy Adult Participants (ARC-24)
Role: lead
A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies
Role: lead
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Role: lead
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
Role: collaborator
AB154 Combined With AB122 for Recurrent Glioblastoma
Role: collaborator
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
Role: lead
Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
Role: collaborator
Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
Role: collaborator
Study of Novel Treatment Combinations in Patients With Lung Cancer
Role: collaborator
A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC
Role: collaborator
Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01
Role: collaborator
Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma
Role: collaborator
Switch Maintenance in Pancreatic
Role: collaborator